Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease

This study has been terminated.

Study NCT00040404. Last updated on November 9, 2007. Information provided by Cephalon

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields
Brief Title ^†	Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
Official Title ^†	A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's Disease
Brief Summary	The purpose of this study is to establish safety for CEP-1347 and to determine an efficacious dose in the treatment of Parkinson's disease.
Detailed Description
Study Phase	Phase II, Phase III
Study Type ^†	Interventional
Study Design ^†	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary Outcome Measure ^†
Secondary Outcome Measure ^†
Condition ^†	Parkinson Disease
Intervention ^†	Drug: CEP-1347
MEDLINE PMIDs
Links	The Parkinson Study Group (PSG) is a non-profit, cooperative group of Parkinson's disease experts from medical centers in the United States and Canada who are dedicated to improving treatment for persons affected by Parkinson's disease.

Recruitment Information Fields
Recruitment Status ^†	Terminated
Enrollment ^†	800
Start Date ^†	March 2002
Completion Date
Eligibility Criteria ^†	Inclusion Criteria: Patients will be included in the study if all of the following criteria are met: Willing and able to give informed consent Age 30 years or older at time of diagnosis of Parkinson's disease Have idiopathic Parkinson's disease with at least 2 cardinal signs of disease: resting tremor, bradykinesia, or rigidity Modified Hoehn and Yahr stage less than or equal to 2.5 Must have had screening procedures for cancer appropriate for the patient's age and gender, within the last 12 months; or be willing to obtain such screening before randomization Women: are not breastfeeding Women: nonchildbearing potential (ie, postmenopausal or surgically sterile) or must use a medically accepted contraceptive regimen for at least 60 days before the baseline visit, and agree to continue such use throughout the duration of the study and for 30 days after the final dose of study drug. Women must be given a pregnancy test unless they are at least 2 years postmenopausal or surgically sterile. Exclusion Criteria: Patients will be excluded from participating in this study if 1 or more of the following criteria are met: Have atypical Parkinsonism due to drugs, metabolic disorders, encephalitis, or other neurodegenerative diseases Have confirmed diagnosis of Parkinson's disease for more than 5 years Have a tremor score of 3 or more in any body part Have any other known medical or psychiatric condition that may compromise participation in the study Have a history of prior malignancy (excluding basal or squamous cell cancer of the skin) within the previous 5 years Have an unresolved abnormal cancer screening test result before randomization Have greater than trace amounts of glycosuria at screening, except for known diabetic patients Have estimated creatinine clearance less than 50 mL/min Have liver function tests (LFT) greater than 3 times the upper limit of normal (ULN) Have any other clinically significant ECG or laboratory finding Have any history of malignant melanoma Have history of seizures (except febrile) or posttraumatic epilepsy Have Mini-Mental State Exam (MMSE) score ≤ 26 Have taken another investigational drug within 60 days before the baseline visit Have received prior treatment with CEP-1347 Have received treatment with agents with potentially confounding anti-Parkinson's disease effects, with specified substrates for CYP3A4/5, or with inhibitors of CYP3A4/5 Received treatment within 6 months before the baseline visit with agents that may induce Parkinson's disease Are expected, within the next 3 months, to reach a level of disability sufficient to require dopaminergic therapy Have BECK depression score ≥ 15 Have known or suspected sensitivity to the investigational study drugs, including B-CIT
Gender	Both
Ages	30 Years and older
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†	United States, Canada, Puerto Rico

Administrative Information Fields
NCT ID ^†	NCT00040404
Organization ID	C1347c/204/PD/US-CA
Secondary IDs ^††
Study Sponsor ^†	Cephalon
Collaborators ^††	H. Lundbeck A/S The Parkinson Study Group
Investigators ^†
Information Provided By	Cephalon
Verification Date	November 2007
First Received Date ^†	June 26, 2002
Last Updated Date	November 9, 2007

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.